Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.

Skor MN, Wonder EL, Kocherginsky M, Goyal A, Hall BA, Cai Y, Conzen SD.

Clin Cancer Res. 2013 Nov 15;19(22):6163-72. doi: 10.1158/1078-0432.CCR-12-3826.

2.

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.

Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ.

Horm Cancer. 2014 Apr;5(2):72-89. doi: 10.1007/s12672-014-0173-2.

3.

Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.

Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD.

Gynecol Oncol. 2015 Sep;138(3):656-62. doi: 10.1016/j.ygyno.2015.06.033.

4.

Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis.

Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD.

Cancer Biol Ther. 2006 Aug;5(8):933-40.

PMID:
16775428
5.

Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.

Agyeman AS, Jun WJ, Proia DA, Kim CR, Skor MN, Kocherginsky M, Conzen SD.

Horm Cancer. 2016 Apr;7(2):114-26. doi: 10.1007/s12672-016-0251-8.

PMID:
26858237
6.

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.

Blanchard Z, Paul BT, Craft B, ElShamy WM.

Breast Cancer Res. 2015 Jan 13;17:5. doi: 10.1186/s13058-014-0512-9.

7.

The rigid steroid 21-hydroxy-6,19-epoxyprogesterone (21OH-6,19OP) is a dissociated glucocorticoid receptor modulator potentially useful as a novel coadjuvant in breast cancer chemotherapy.

Orqueda AJ, Dansey MV, Español A, Veleiro AS, Bal de Kier Joffé E, Sales ME, Burton G, Pecci A.

Biochem Pharmacol. 2014 Jun 15;89(4):526-35. doi: 10.1016/j.bcp.2014.04.006.

PMID:
24735610
9.

CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF.

Breast Cancer Res. 2012 Apr 26;14(2):R68.

10.

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.

Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL.

J Clin Invest. 2013 Mar;123(3):1348-58. doi: 10.1172/JCI65416.

11.

Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.

Regan Anderson TM, Ma SH, Raj GV, Cidlowski JA, Helle TM, Knutson TP, Krutilina RI, Seagroves TN, Lange CA.

Cancer Res. 2016 Mar 15;76(6):1653-63. doi: 10.1158/0008-5472.CAN-15-2510.

PMID:
26825173
12.

Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.

Schettini F, Giuliano M, De Placido S, Arpino G.

Cancer Treat Rev. 2016 Nov;50:129-141. doi: 10.1016/j.ctrv.2016.09.004. Review.

PMID:
27665540
13.
14.

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.

Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.

BMC Cancer. 2015 Mar 3;15:89. doi: 10.1186/s12885-015-1090-7.

15.

MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.

Liu X, Tang H, Chen J, Song C, Yang L, Liu P, Wang N, Xie X, Lin X, Xie X.

Oncotarget. 2015 Aug 21;6(24):20070-83.

16.

Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.

Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL.

Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38. doi: 10.1073/pnas.1421438111.

17.

Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line.

Takahashi K, Tanaka M, Inagaki A, Wanibuchi H, Izumi Y, Miura K, Nagayama K, Shiota M, Iwao H.

Int J Oncol. 2013 Dec;43(6):1985-91. doi: 10.3892/ijo.2013.2135.

PMID:
24126575
18.

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.

Nanda R, Stringer-Reasor EM, Saha P, Kocherginsky M, Gibson J, Libao B, Hoffman PC, Obeid E, Merkel DE, Khramtsova G, Skor M, Krausz T, Cohen RN, Ratain MJ, Fleming GF, Conzen SD.

Springerplus. 2016 Jun 30;5(1):947. doi: 10.1186/s40064-016-2457-1.

19.

Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.

Gründker C, Föst C, Fister S, Nolte N, Günthert AR, Emons G.

Breast Cancer Res. 2010;12(4):R49. doi: 10.1186/bcr2606.

20.

Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis.

Wen J, Yeo S, Wang C, Chen S, Sun S, Haas MA, Tu W, Jin F, Guan JL.

Breast Cancer Res Treat. 2015 Feb;149(3):619-29. doi: 10.1007/s10549-015-3283-9.

Items per page

Supplemental Content

Support Center